

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: EISENBACH4A

In re Application of:)	Conf. No.: 8693
Lea EISENBACH)	
)	Art Unit:
)	
IA Filed: July 28, 2003)	Examiner:
)	
Appln. No.: 10/524,787)	Washington, D.C.
)	
)	September 23, 2005
For: TUMOR ASSOCIATED ANTIGEN...)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114.

[X] 2. In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR \$1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.


[X] 3. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

4. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR \$1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Registration No.20,520

SN:ses
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\Y\YEDA\eisenbach4a\pto\ids.fee21SE2005.doc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/524,787
Filing Date	July 28, 2003
First Named Inventor	Lea EISENBACH
Group Art Unit	
Examiner Name	
Attorney Docket Number	EISENBACH4A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AO	CARMON, L et al "Novel Breast-Tumor-Associated MUC1-Derived Peptides: Characterization in Db-/X β 2 Microglobulin (β 2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D ^b - β 2 Microglobulin Single Chain" Int. J. Cancer 85 (2000) pp:391-397	
	AP	CARMON, L et al "Characterization of novel breast carcinoma-associated BA46-derived peptides in HLA-A2.1D ^b - β 2m transgenic mice: J. Clin. Invest. 110 (2002) pp: 453-462	
	AQ	CELIS, ESTEBAN et al "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes" Proc. Natl. Acad. Sci. Vol. 91, (March 1984) pp: 2105-2109	
	AR	CONROY, R.M. et al "Phase I Trial of a Recombinant Vaccinia Virus Encoding Carcinoembryonic Antigen in Metastatic Adenocarcinoma: Comparison of Intradermal versus Subcutaneous Administration" Clin Cancer Res. 5 (1999) pp 2330-2337.	
	AS	DEBLANDRE, GISELE A. et al "Expression Cloning of an Interferon-inducible 17-kDa Membrane Protein Implicated in the Control of Cell Growth" The J. of Biological Chemistry Vol. 270, No. 40 (October 1995) pp:23860-23866	
	AT	FIRAT, H et al "Comparative analysis of the CD8 ⁺ T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice" Int. Immunol. 14 (2002) pp:925-934	
	AU	FONG, LAWRENCE, et al "Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization: Implications for Immunotherapy of Prostate Cancer" The J. of Immunology (1997) pp:3113-3117	
	AV	HISAMATSU, TADAKAZU, et al "Interferon-inducible Gene Family 1-8U Expression in Colitis associated Colon Cancer and Severely Inflamed Mucosa in Ulcerative Colitis" J. Cancer Research 59 (1999) pp:5927-5931	
	AW	KAWAKAMI, YUTAKA et al "Recognition of Multiple Epitopes in the Human Melanoma Antigen gp100 by Tumor-Infiltrating T Lymphocytes Associated with In Vivo Tumor Regression" The J. of Immunology (1995) pp:3961-3968	
	AX	LEWIN, ANDREW R. et al "Molecular Analysis of a Human interferon-inducible gene family" J. Biochem. 199 (1991) pp:417-423	
	AY	MACHLENKIN, A et al "Human CTL Epitopes Prostatic Acid Phosphates-3 and Six-Transmembrane Epithelial Antigen of Prostate-3 as Candidates for Prostate Cancer Immunotherapy" Cancer Res. 65 (2005) pp: 6435-6442	
	AZ	MANDELBOIM, OFER et al "Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides" Nature Medicine, Vol 1, No. 11, (November 1995) pp:1179-1183	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Sheet	2	of	2	Application Number	10/524,787
				Filing Date	July 28, 2003
				First Named Inventor	Lea EISENBACH
				Group Art Unit	
				Examiner Name	
				Attorney Docket Number	EISENBACH4A

BA	MOLLER, P. et al "Small ISGs Coming Forward" J. Interferon Cytokine Res. 24 (2004) pp: 1-19	
BB	MURPHY, G.P. et al "Infusion of Dendritic Cells pulsed with HLA-A2-Specific Prostate-Specific Membrane Antigen Peptides: A Phase II Prostate Cancer Vaccine Trial Involving Patients with Hormone-Refractory Metastatic Disease" Prostate 38 (1999) pp: 73-78	
BC	PASCOLO, STEVE et al "HLA-A2.1-restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β 2 Microglobulin (β 2m) HLA-A2.1 Monochain Transgenic H-2D ^b β 2m Double Knockout Mice" J. Exp. Med. Vol. 185, No. 12, (June 1997) pp: 2043-2051	
BD	TJOA, B.A. "Follow-Up Evaluation of a Phase II Prostate Cancer Vaccine Trial" The Prostate 40 (1999) pp: 125-129	
BE	XU, LINDA L. et al "PSGR, a Novel Prostate-specific Gene with Homology to a G Protein-coupled Receptor, Is Overexpressed in Prostate Cancer" Cancer Research 60 (December 2000) pp:6568-6572	
BF	ZHANG, LIN et al "Gene Expression Profiles in Normal and Cancer Cells" Science Vol. 276 (May 1997) pp:1268-1272	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.